Foldrx Pharms Company Profile
✉ Email this page to a colleague
What is the competitive landscape for FOLDRX PHARMS, and what generic alternatives to FOLDRX PHARMS drugs are available?
FOLDRX PHARMS has two approved drugs.
There are three US patents protecting FOLDRX PHARMS drugs.
There are fifty-seven patent family members on FOLDRX PHARMS drugs in twenty-seven countries and fourteen supplementary protection certificates in thirteen countries.
Drugs and US Patents for Foldrx Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | 7,214,695 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | 9,770,441 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | 7,214,695 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Foldrx Pharms | VYNDAMAX | tafamidis | CAPSULE;ORAL | 212161-001 | May 3, 2019 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | |||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Foldrx Pharms
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | 8,168,663 | ⤷ Try a Trial |
Foldrx Pharms | VYNDAQEL | tafamidis meglumine | CAPSULE;ORAL | 211996-001 | May 3, 2019 | 8,653,119 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for Foldrx Pharms Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 5756151 | ⤷ Try a Trial |
Singapore | 11201700958Y | ⤷ Try a Trial |
Germany | 122012000007 | ⤷ Try a Trial |
Denmark | 1587821 | ⤷ Try a Trial |
Taiwan | I644902 | ⤷ Try a Trial |
South Korea | 101089904 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Foldrx Pharms Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
1587821 | 6/2012 | Austria | ⤷ Try a Trial | PRODUCT NAME: TAFAMIDIS; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
1587821 | 126 5003-2012 | Slovakia | ⤷ Try a Trial | PRODUCT NAME: TAFAMIDIS MEGLUMIN; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
1587821 | 382 | Finland | ⤷ Try a Trial | |
1587821 | CR 2012 00006 | Denmark | ⤷ Try a Trial | PRODUCT NAME: TAFAMIDIS (SOM MEGLUMIN); REG. NO/DATE: EU/1/11/717/001 20111116 |
1587821 | C01587821/01 | Switzerland | ⤷ Try a Trial | PRODUCT NAME: TAFAMIDIS; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67083 09.03.2020 |
1587821 | C300516 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: TAFAMIDIS, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT, IN HET BIJZONDER TAFAMIDIS MEGLUMINE ZOUT; REGISTRATION NO/DATE: EU/1/11/717/001 20111116 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.